POU5F1 and breast carcinoma: The efficacy of activating other pro-tumorigenic pathways, such as PKA signaling by CW008, Oct4 signaling by OAC2, and PI3K signaling by YS49, can be evaluated in inhibiting varying types of breast cancer.